Stevens-Johnson Syndrome is an extremely painful and potentially deadly condition that can be caused by several medications, including Lamictal. Childers, Schlueter & Smith has recently filed several lawsuits involving Lamictal, Stevens-Johnson Syndrome, and the negligence of healthcare providers involved in the administration of this medication.
What is Lamictal?
Lamictal, also known as Lamotrigine, is prescribed to patients to treat seizures, epilepsy, and also bipolar disorder. Any doctor prescribing Lamictal and any pharmacist dispensing Lamictal should be aware of the association between Lamictal and Stevens-Johnson Syndrome, and should provide patients with proper guidance about these risks.
The FDA has required that the manufacturers of Lamictal include a black box warning on its package specifically related to Stevens-Johnson Syndrome. The black box warning states:
According to the FDA’s black box warning, the rate of serious rash is greater in pediatric patients than in adults. Despite clear warnings from the FDA, many healthcare professionals continue to prescribe Lamictal in increasing amounts, escalate the dose too quickly, and fail to provide any guidance to their patients about this potentially lethal side effect.
Prompt treatment of Stevens-Johnson Syndrome, particularly in a specialty unit or burn unit, can greatly reduce the symptoms of the condition and may even save the patient’s life. This illustrates why proper guidance and dosing is critically important to patient safety, and why it is important for patients who are taking Lamictal to carefully look for any signs of a rash, and to both seek immediate treatment and contact their prescribing physician or pharmacist if one develops.